<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754793</url>
  </required_header>
  <id_info>
    <org_study_id>33501-B</org_study_id>
    <secondary_id>1KL2RR025015-01 (NIH)</secondary_id>
    <secondary_id>1KL2RR025015-01</secondary_id>
    <nct_id>NCT00754793</nct_id>
  </id_info>
  <brief_title>Sinusitis and Facial Pain Disorders Anti-Depression Trial</brief_title>
  <acronym>SFPAT</acronym>
  <official_title>Sinusitis and Facial Pain Disorders Anti-Depression Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that the addition of an antidepressant to the standard treatment
      regimen in patients with both chronic sinusitis and depression or facial pain disorders and
      depression will decrease the report of chronic sinusitis or facial pain symptom severity.

      This is a stratified, randomized, double-blind, placebo-controlled study using the drug
      escitalopram for the treatment of depression in patients experiencing depression and chronic
      sinusitis or depression and facial pain disorders.

      It is a 12-week study. Subjects will have a screening visit and then be followed up by phone
      weekly for four weeks and bi-weekly for 8 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients presenting to the University of Washington Medical Center Sinus Clinic are
      screened for depression with the PHQ-9 as a standard of care in their evaluation, as well as
      a physical examination, nasal endoscopy, and CT scan. Those patients who meet diagnostic
      criteria for CRS and for major depression will then be treated with three weeks of maximal
      medical therapy. Maximal medical therapy includes three weeks of a second-line antibiotic
      (such as Augmentin, azithromycin, or a fluoroquinolone), possible oral steroids based on the
      presence of inflammation or polyps in the sinuses, and nasal saline irrigations. They will
      then follow up with Dr. Davis in one month from their initial evaluation. Those who still do
      not have significantly improved symptoms (considered medical failures) will be approached and
      introduced to the study by Dr. Davis's medical assistant and then referred to the research
      assistant for further discussion and offered enrollment and consent if entry criteria are
      met. Note that if patients present for their initial consultation and have received maximal
      medical therapy from the referring clinician within the past two months, then they will be
      approached for possible entry into the study at that time.

      Patients presenting with complaints of facial discomfort will also be included. These people
      often present with subjective sinusitis-like symptoms that are not objectively supported by
      CT scan or endoscopy. These patients are referred to the Neurology Clinic and will be asked
      to defer their appt. for the duration of the study.

      Both patients and clinician will be blinded to the drug assignment. Subjects will be
      stratified according to facial pain or chronic sinusitis and then randomization will be done
      by restricted block randomization. A letter will be sent to each patient's primary care
      provider explaining this trial and that their patient may be taking an anti-depressant or a
      placebo.

      During the trial, the dose of escitalopram will start at 10mg per day for seven days followed
      by 20mg per day for fourteen days, then will be maintained or titrated up based on our
      study's titration protocol.

      At the conclusion of three months of active drug, the patient will be given the opportunity
      to continue the medication through their primary care provider. A two week supply of the
      active anti-depressant will be available to buffer this transition for patient's randomized
      to escitalopram.

      Data Collection Phase 0: Recruitment All patients who meet criteria of CRS and depression or
      facial pain and depression will be monitored to determine how many patients were excluded and
      for what reasons. This is imperative for Specific Aim 1, to collect the data necessary to
      eventually calculate sample size and recruitment times for a future definitive trial.

      Phase I: Patient Baseline Initial clinical, radiographic, and co-morbid characteristics will
      be identified using questionnaires and a short personal interview (by the study research
      assistant) as described below immediately following the initial one-month follow-up visit
      with Dr. Davis

      Phase II: Patient Follow-up Subjects will be followed closely with weekly phone calls from
      the research assistant for the first four weeks of the trial. During these events, the PHQ-9
      will be administered and questions will be asked regarding adverse events and side effects.
      After this, subjects will be telephoned bi-weekly for the duration of the trial asking the
      same questions. In addition, at one month and three months after the initiation of the
      research drug, during the telephone interview, subjects will be administered four
      questionnaires: the SNOT-20, SF-12, PHQ-9, and the SCL-20. Chronic sinusitis subjects and
      facial pain subjects will complete identical forms as there is common symptom crossover.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sino-Nasal Outcome Test-20 (SNOT-20)</measure>
    <time_frame>baseline, 1 month, 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Chronic Sinusitis</condition>
  <condition>Facial Pain Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>escitalopram 10mg - 30mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>10mg - 30mg daily titrated as tolerated over 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lexapro (escitalopram)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>inactive comparator; titrated as per protocol over 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  meet diagnostic criteria for chronic sinusitis

          -  meet diagnostic criteria for facial pain disorder

          -  meet criteria for major depressive disorder on the PHQ-9

          -  18 years of age or older

          -  established primary care provider

          -  able to read and speak English

        Exclusion Criteria:

          -  unable to give informed consent of unable to complete self-administered questionnaires
             due to cognitive impairment, language barriers or severe medical condition

          -  terminal illness or significantly immunocompromized

          -  complications from chronic rhinosinusitis

          -  presence of sinus tumor

          -  isolated sphenoid disease

          -  immotile cilia syndrome

          -  currently on anti-depressant or mood stabilizer med.

          -  diagnosis of bipolar disorder, schizophrenic disorders, paranoid disorders, or
             psychotic disorders NOS

          -  significant suicide risk

          -  history of hospitalization for mental disorders including psychosis or depression

          -  history of drug abuse within prev. 6 months or dependency on any drug, including
             alcohol

          -  pregnant or breast feeding

          -  women of child-bearing potential not currently using an approved method of birth
             control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg E Davis, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <results_first_submitted>June 13, 2012</results_first_submitted>
  <results_first_submitted_qc>June 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2012</results_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Greg Davis</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Facies</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited patients with chronic sinusitis and depression (PHQ9&gt;=10) who were not already on an antidepressant.</recruitment_details>
      <pre_assignment_details>No adverse events. No exclusions post enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Drug (Lexapro)</title>
          <description>escitalopram 10mg - 30mg daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>voluntary withdrawn from study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Drug (Lexapro)</title>
          <description>escitalopram 10mg - 30mg daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="45"/>
                    <measurement group_id="B2" value="50" spread="50"/>
                    <measurement group_id="B3" value="48" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sino-Nasal Outcome Test-20 (SNOT-20)</title>
        <time_frame>baseline, 1 month, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Drug (Lexapro)</title>
            <description>escitalopram 10mg - 30mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo drug</description>
          </group>
        </group_list>
        <measure>
          <title>Sino-Nasal Outcome Test-20 (SNOT-20)</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Drug (Lexapro)</title>
          <description>escitalopram 10mg - 30mg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo drug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Greg E. Davis, MD MPH</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-543-5230</phone>
      <email>gedavis@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

